In this study, the anticancer effect of prednisolone was investigated using rats with normal endogen adrenaline levels (intact), reduced adrenaline levels (metyrosine-induced) and adrenaline deficiency (adrenalectomized) via gastric adenocarcinoma model. Gastric adenocarcinoma was induced with N-methyl-N 0 -nitro-N-nitrosoguanidine (MNNG). According to our experimental results, prednisolone could not prevent MNNG-induced adenocarcinoma when used alone in intact rats. There were neither macroscopic nor microscopic signs of cancer in the rat groups that received metyrosine and prednisolone. However, dysplasia occurred in the stomachs of 2 of 10 rats that received metyrosine and prednisolone. There was no adenocarcinoma genesis in the stomachs of adrenalectomized rats that received prednisolone alone. However, yohimbine (a selective blocker of a2-adrenoreceptors) pretreatment in adrenalectomized rats negated the anticancer effect of prednisolone. In conclusion, prednisolone was shown not to be an anticancer agent in intact rats when used alone; however, it has anticancer effects in rats whose adrenaline levels were reduced via adrenalectomy or metyrosine, which is a catecholamine synthesis inhibitor.Although many anticancer drugs are available, they are often ineffective. It has been reported that there are over 1,400,000 patients with gastroesophageal cancer worldwide. 1,2 Approximately 800,000 patients reportedly die as a result of this cancer. 3 There is a 5-year survival rate of 60% in Japan and a 5-year survival rate of 23% in the USA. 4 In 2000, 650,000 of 880,000 patients with stomach cancer died. 5 Stomach cancer is the second most common cancer in the world and is one of the leading causes of cancer-related deaths. 6-9 Approximately 90% of stomach cancers are adenocarcinomas. The genesis of stomach cancers is a complex process related to multifactorial etiologies. 10 Previous findings indicate that increased sympathetic nervous system activity enhances the development of gastric cancers, and suppression of sympathetic nervous system activity inhibits carcinogenesis. 11,12 The role of catecholamines are important in different cancer types because of their regulatory effects on tumor angiogenesis, [13][14][15][16] which is critical for the growth and progression of malignant tumors. 17 Bromocriptine is a dopamine receptor agonist known to enhance gastric carcinogenesis induced by Nmethyl-N 0 -nitro-N-nitrosoguanidine (MNNG) in Wistar rats. 18 Fitzgerald suggested there are multiple lines of evidence indicating that an elevated level of norepinephrine may be an etiological factor in various types of cancer. 19 Such previous data points to the role of catecholamines in cancer genesis.It is well known today that chronic inflammation also leads to the development of cancer, 20 suggesting that antiinflammatory drugs can play a role in cancer treatment. Using vitamin C, vitamin E, carotene and nonsteroidal antiinflammatory drugs (NSAIDs) reduces the risk of stomach cancers. It is thought that the anticancer effect...